Well, that's what Dr. Peter Slavin, president of Massachusetts General Hospital, told STAT news in a story about Harvard's revised conflict of interest policy: Slavin said the change may help with a recruitment problem: “Some faculty don’t come because they perceive that Harvard Medical School has rules that are much too restrictive.” Or they leave, according … Continue reading Docs reject Harvard jobs because of conflict of interest policy?
The debate over potential bias at the Duke Clinical Research Institute emerging fro this morning's Avandia hearing inspired a trip to the archives. This story looked at many of the same issues, which came up when the Duke clinical trials operation was young. By Tinker Ready from The Raleigh News & Observer Genentech and university … Continue reading Avandia, the Duke Clinical Research Institute and conflict of interest
And some comments from the Knight Science Journalism Tracker: A new cystic fibrosis drug--the first to be developed based on understanding of the genetics of the illness--is an orphan drug that can help only about 4 percent of patients with cystic fibrosis. Its financial toxicity is such that it can destroy the finances of those … Continue reading A closer look at the downside of the Vertex – Cystic Fibrosis Foundation deal
It does have the magic "H" word in its name. (Not the be confused with Harvard Vanguard, a group of now unrelated clinics and health centers.) From today's Globe: A Boston Globe analysis of contributor reports shows that in seven months (Republican Charlie) Baker’s campaign raised more than $122,000 in contributions tied directly to … Continue reading Harvard Pilgrim for Governor
The pharma watchdogs at Gooz News point out that: The latest New England Journal of Medicine contains a scathing perspective denouncing the Senate's health care reform bill for giving industry too much control over a new comparative effectiveness research (CER) agency, an issue I tried to call attention to in Health Tech Review (Sept. 28, … Continue reading Tufts doc warns of industry influence on health reform